ehaweb.org
NRF2 AS A THERAPEUTIC TARGET IN ACUTE LEUCEMIA – IN VITRO STUDIES WITH OLTIPRAZ
EHA Library, Raquel Alves, 324036
MELFLUFEN PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA EXPOSED AND/OR REFRACTORY TO PRIOR ALKYLATORS – A POOLED ANALYSIS OF THE O-12-M1 AND HORIZON STUDIES
EHA Library, Paula Rodríguez-Otero, 325731
EFFICACY AND SAFETY OF SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE BASED ON REFRACTORY STATUS TO LENALIDOMIDE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: A POST-HOC ANALYSIS OF THE BOSTON STUDY
EHA Library, Xavier Leleu, 325732
SURVIVAL AMONG OLDER PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA TREATED WITH SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE (XVD) IN THE BOSTON STUDY
EHA Library, Thierry Facon, 325734
MATCHING ADJUSTED INDIRECT COMPARISON OF CILTACABTAGENE AUTOLEUCEL VERSUS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH ≥3 LINES OF PRIOR THERAPY
EHA Library, Katja Weisel, 325736
FIRST-LINE THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA: FINAL RESULTS OF THE OBSERVATIONAL STUDY FIRST-NIS
EHA Library, Holger Nückel, 325737
CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS KD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF TIME TO NEXT TREATMENT, TIME TO PROGRESSION, AND PROGRESSION-FREE SURVIVAL FOR NEXT THERAPY
EHA Library, Saad Z. Usmani, 325740
DEVELOPMENT OF ANTIBODY RESPONSE TO SARS-COV-2 FOLLOWING ASYMPTOMATIC INFECTION IN PATIENTS WITH PLASMA CELL DISORDERS ON IMMUNOMODULATORY THERAPY
EHA Library, Wei Yee Chan, 325741
CHARACTERISTICS OF NEUROTOXICITY ASSOCIATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PIVOTAL PHASE 2 KARMMA STUDY
EHA Library, Salomon Manier, 325742
REAL-WORLD DURATION OF TREATMENT (DOT) WITH LENALIDOMIDE-DEXAMETHASONE (RD)-BASED REGIMENS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): OUTCOMES FROM THE GLOBAL INSIGHT MM STUDY
EHA Library, Noemi Puig, 325743
POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A SAFETY SUBANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL
EHA Library, Katja Weisel, 325746
SURVIVAL AND OUTCOMES OF NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS STRATIFIED BY TRANSPLANT STATUS DIAGNOSED BETWEEN 2007-2018: REAL-WORLD ANALYSIS FROM THE CANADIAN MYELOMA RESEARCH GROUP DATABASE
EHA Library, Hira Mian, 325747
COMPARISON OF CILTACABTAGENE AUTOLEUCEL VERSUS CONVENTIONAL TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Library, Luciano J. Costa, 325748
OVERVIEW AND EVOLUTION OF TREATMENT LINES IN MULTIPLE MYELOMA FROM 2014 TO 2018: A RETROSPECTIVE STUDY USING THE FRENCH NATIONAL CLAIM DATABASE (SNDS)
EHA Library, Aurore Perrot, 325752
AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA: IMPROVEMENT IN IMMEDIATE RESULTS USING NON-CRYOPRESERVED STEM CELLS
EHA Library, Pilar Dutari, 325754
Clinical Advances With Epigenetic Targets in T-Cell Lymphomas
EHA Library, S Horwitz, 337278
Summary and Panel Discussion
EHA Library, S Horwitz, 337280
Q&A
EHA Library, S Horwitz, 337281
Epigenetic Targets in T-Cell Lymphomas
EHA Library, J Fitzgibbon, 337282
Epigenetic Targets in B-Cell Lymphomas
EHA Library, J Fitzgibbon, 337283
Panel discussion and concluding remarks
EHA Library, P Moreau, 337288
FRESH PERSPECTIVES ON ENDURING CONVERSATIONS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Library, P Moreau, 337289
Welcome and Introduction
EHA Library, X Leleu, 337295
Targeted immune stimulation in myeloma: Immuno- and cellular therapies
EHA Library, N Raje, 337300
Story of hope – Key decisions in relapse treatment
EHA Library, MA Dimopoulos, 337303
Set new goals – New momentum in first-line therapy
EHA Library, O Landgren, 337305
A bright future - Evaluation of emerging therapies
EHA Library, G Cook, 337306
THE EVOLVING TREATMENT PARADIGM IN MYELOFIBROSIS
EHA Library, J Garcia, 337307
Q&A and discussion
EHA Library, K Linton, 337310
Closing remarks
EHA Library, K Linton, 337311
Integrating cell therapies in the treatment of DLBCL
EHA Library, P Barba, 337312
CAR T cell therapy in CLL: latest achievements and perspectives
EHA Library, A Kittai, 337314
The Role of Emerging Treatments and Management Approaches in Cold Agglutinin Disease
EHA Library, A Röth, 337316
Pathophysiology of Cold Agglutinin Disease – Understanding the Complement System
EHA Library, S Berentsen, 337320
Panel discussion: Beyond chemotherapy: advancing the treatment of ALL with immuno-oncology therapy
EHA Library, R Foà, 337322
Treatment of first relapse in childhood BCP-ALL
EHA Library, F Locatelli, 337324
Consolidation therapy for adult ALL: targeting minimal residual disease
EHA Library, N Gökbuget, 337325
Evolving approaches to treating early ITP
EHA Library, V McDonald, 337326
AML treatment choices: key data and perspectives
EHA Library, MT Voso, 337328
Introduction to MF treatment and management
EHA Library, F Cervantes, 337330
The evolution of MF treatment - how I manage MF today
EHA Library, J Mascarenhas, 337331
Preparing for the future of MF management
EHA Library, A Reiter, 337332
How I manage AML in the era of novel treatments, plus panel discussion
EHA Library, E Stein, 337333
Interactive panel discussion and Q&A
EHA Library, A Davies, 337334
Introduction
EHA Library, M Machaczka, 337339
Case 2: For Sherlock Holmes it’s never too late
EHA Library, A Pession, 337344
Post-session Survey
EHA Library, G Jackson, 337348
Case-Based Discussion: Treatment Across the Spectrum of Relapsed/Refractory Disease
EHA Library, G Jackson, 337349
The Monoclonal Antibody Landscape in Relapsed/Refractory Multiple Myeloma
EHA Library, E Ocio, 337350
Assessment of Measurable Residual Disease (MRD) Status for the Management of Patients with Acute Lymphoblastic Leukemia (ALL).
EHA Library, E Jabbour, 337376
SUBGROUP ANALYSIS: EFFICACY AND SAFETY OF ORAL PANOBINOSTAT IN COMBINATION WITH SC BORTEZOMIB AND ORAL DEXAMETHASONE IN RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS > 75 YEARS OF AGE
EHA Library, Fredrik Schjesvold, 325733
COMPARISON OF OUTCOMES WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-1 VERSUS STANDARD OF CARE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA PATIENTS IN CLINICAL TRIALS OF DARATUMUMAB
EHA Library, Katja Weisel, 325735
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN ELDERLY PATIENTS WITH RELAPSED MULTIPLE MYELOMA: IKEMA SUBGROUP ANALYSIS
EHA Library, Thierry Facon, 325738
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: IKEMA SUBGROUP ANALYSIS
EHA Library, Ivan Spicka, 325739
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA ACCORDING TO PRIOR LINES OF TREATMENT AND REFRACTORY STATUS: IKEMA SUBGROUP ANALYSIS
EHA Library, Meletios-Athanasios Dimopoulos, 325744
A PROSPECTIVE, NON-INTERVENTIONAL, MULTINATIONAL STUDY OF REAL-LIFE STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH ≥3 PRIOR LINES OF THERAPY: INTERIM DATA FROM LOCOMMOTION
EHA Library, María-Victoria Mateos, 325745
A MULTINATIONAL CHART REVIEW OF REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Library, K. Martin Kortüm, 325749
PULMONARY FUNCTION TESTS REVEAL UNRECOGNIZED LUNG DYSFUNCTION AND HAVE INDEPENDENT PROGNOSTIC SIGNIFICANCE IN PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS
EHA Library, Despina Fotiou, 325750
EFFECTIVENESS AND SAFETY OF IXAZOMIB-BASED THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) OUTSIDE OF A CLINICAL TRIAL: FINAL ANALYSIS OF THE ‘USE VIA EARLY ACCESS TO IXAZOMIB’ (UVEA IXA) STUDY
EHA Library, Heinz Ludwig, 325751
EXOSOMAL CIRCRNA CACNG2 IS A NOVEL BIOMARKER FOR MM-RELATED CARDIAC DISEASES
EHA Library, Manya Yu, 325753
CLINICAL VALUE OF MINIMAL RESIDUAL DISEASE ASSESSED BY MULTIPARAMETER FLOW CYTOMETRY IN AMYLOID LIGHT CHAIN AMYLOIDOSIS
EHA Library, Juan Li, 325755
EPIDEMIOLOGY OF MULTIPLE MYELOMA: DATA FROM THE FRENCH NATIONAL HEALTH INSURANCE DATABASE (SNDS)
EHA Library, Cyrille Touzeau, 325756
Introduction
EHA Library, S Horwitz, 337277
Q&A
EHA Library, S Horwitz, 337279
Clinical Advances With Epigenetic Targets in B-Cell Lymphomas
EHA Library, C Sarkozy, 337284
DELVING DEEP INTO CLL
EHA Library, M Hallek, 337287
CAR T cell therapy: Clinical and practical aspects
EHA Library, X Leleu, 337296
Discussion and Q&A
EHA Library, X Leleu, 337297
The importance of immune microenvironment in multiple myeloma and current treatment landscape
EHA Library, P Rodriguez Otero, 337298
Broad immune stimulation in myeloma: The role of cereblon modulators
EHA Library, P Richardson, 337299
THE CHANGING FACE OF AML INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
EHA Library, G Roboz, 337301
Introduction
EHA Library, MA Dimopoulos, 337302
Panel discussion & concluding remarks
EHA Library, MA Dimopoulos, 337304
Welcome and introduction
EHA Library, K Linton, 337308
Indolent NHL: current practices and new treatment paradigm
EHA Library, K Linton, 337309
Immuno-oncology agents in the treatment landscape of cHL
EHA Library, M André, 337313
Welcome, Introductions Pre-Test
EHA Library, A Röth, 337315
Post-test and Q&A
EHA Library, A Röth, 337317
Methods to Facilitate Early and Accurate Diagnosis in Cold Agglutinin Disease
EHA Library, W Barcellini, 337318
The Burden of Cold Agglutinin Disease
EHA Library, C Broome, 337319
Frontline therapy of adult Ph-positive ALL
EHA Library, R Foà, 337321
Welcome and introduction
EHA Library, R Foà, 337323
Putting theory into practice: case-based discussions around early ITP
EHA Library, V McDonald, 337327
Panel discussion and closing remarks
EHA Library, F Cervantes, 337329
Where are we now with the management of follicular lymphoma?
EHA Library, A Davies, 337335
New challenges in the evolving follicular lymphoma treatment landscape
EHA Library, K Hübel, 337336
Case discussion: What can we do to optimise initial therapy in follicular lymphoma?
EHA Library, M Caballero, 337337
Case discussion: How can we improve the management of relapsed/refractory follicular lymphoma?
EHA Library, T Vassilakopoulos, 337338
Live Q&A and conclusions
EHA Library, M Machaczka, 337340
Case 3: It’s simple Watson – persistence pays off!
EHA Library, M Machaczka, 337341
Case 4: Solving the case of the White Storm
EHA Library, H Rosenbaum, 337342
Case 1: A case of double trouble
EHA Library, H Rosenbaum, 337343
Case 5: Holmes and Watson’s involvement is only skin-deep
EHA Library, A Pession, 337345
Monoclonal Antibodies in Multiple Myeloma: New Trials and Combinations
EHA Library, F Schjesvold, 337346
Welcome and Introductions
EHA Library, G Jackson, 337347
Audience Q & A
EHA Library, C Bygrave, 337351
IMCD IS NOT AN INDOLENT DISEASE: REAL-WORLD EVIDENCE SUGGESTS WE MUST ACT IMMEDIATELY
EHA Library, M Streetly, 337352
Monitoring Measurable Residual Disease (MRD) for Clinical Decision-Making in Acute Lymphoblastic Leukemia (ALL)
EHA Library, L Muffly, 337377
The Relevance of TCR Sequencing-Based Determination of the Cellular Immune Response in SARS-CoV-2 Infection
EHA Library, G Tonon, 337378
Panel Discussion
EHA Library, G Tonon, 337379

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings